Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer – Pipeline Review, H2 2016, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 26, 106, 110, 9, 145, 36 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 15, 8, 22 and 3 molecules, respectively.
Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
2cureX ApS
3-V Biosciences Inc
3M Drug Delivery Systems
3SBio Inc
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Accelerated Pharma Inc
Adamed Sp z oo
Aduro BioTech Inc
Advenchen Laboratories LLC
Alchemia Ltd
Allinky Biopharma
Amal Therapeutics SA
amcure GmbH
Amgen Inc
Antibe Therapeutics Inc
Apac Biotech Pvt Ltd
Apexigen Inc
Aphios Corp
Aposense Ltd
Arisaph Pharmaceuticals Inc
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
ATLAB Pharma SAS
AVEO Pharmaceuticals Inc
B Cell Design SAS
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bionomics Ltd
Bionovis SA
Biotecnol Ltd
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Burzynski Research Institute Inc
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Carna Biosciences Inc
Cascadian Therapeutics Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Cellceutix Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celltrion Inc
Celyad SA
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
ChoDang Pharm Co Ltd
Cipla Ltd
Cleave Biosciences Inc
Cleveland BioLabs Inc
COARE Biotechnology Inc
Coherus BioSciences Inc
Compugen Ltd
Cornerstone Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
Cytune Pharma SAS
Daiichi Sankyo Company Ltd
DanDrit Biotech A/S
Deciphera Pharmaceuticals LLC
Dicerna Pharmaceuticals Inc
Double Bond Pharmaceutical International AB
Dr. Reddy's Laboratories Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Company
Endor Nanotechnologies SL
enGene Inc
EnGeneIC Ltd
Ensol Biosciences Inc
EntreChem SL
Enzo Biochem Inc
Etubics Corp
Exelixis Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Formosa Laboratories Inc
Fusion Antibodies Ltd
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
Genoscience Pharma
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glycotope GmbH
Golden Biotechnology Corp
Green Cross Corp
Hadasit Medical Research Services & Development Ltd
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
Hemispherx Biopharma Inc
Hutchison MediPharma Ltd
iDD biotech SAS
Ideaya Biosciences Inc
Ignyta Inc
Immodulon Therapeutics Ltd
ImmuneXcite Inc
Immunomedics Inc
Immunovative Therapies Ltd
Incanthera Ltd
Incyte Corp
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Interprotein Corp
Intezyne Technologies Inc
Ionis Pharmaceuticals Inc
IPD Therapeutics BV
Isofol Medical AB
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KaloBios Pharmaceuticals Inc
Kancera AB
Karyopharm Therapeutics Inc
Kura Oncology Inc
Laboratorio ELEA SACIF y A
Lee's Pharmaceutical Holdings Ltd
Lion Biotechnologies Inc
LipoMedix Pharmaceutical Inc
Loxo Oncology, Inc.
Mabion SA
Mabtech Ltd
mAbxience SA
MacroGenics Inc
Marina Biotech Inc
MediaPharma srl
MedImmune LLC
Medinet Co Ltd
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
Microlin Bio, Inc.
MolMed SpA
Mologen AG
Morphotek Inc
Multimmune GmbH
Mycenax Biotech Inc
Natco Pharma Ltd
NatureWise Biotech & Medicals Corp
Nektar Therapeutics
Neovacs SA
Nerviano Medical Sciences Srl
Nippon Kayaku Co Ltd
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
Novogen Ltd
Noxxon Pharma AG
NuCana BioMed Ltd
OBI Pharma Inc
Oncobiologics Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
Otsuka Holdings Co Ltd
Oxford BioMedica Plc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pivot Pharmaceuticals Inc
Pivotal BioSciences Inc
PlantForm Corp
PLx Pharma Inc
Precision Biologics Inc
Prima BioMed Ltd
Propanc Health Group Corp
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
R Pharm
RedHill Biopharma Ltd
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Samumed LLC
Sanofi
Selvita SA
Shanghai Henlius Biotech Co Ltd
Shire Plc
Sigma-Tau SpA
Sigmoid Pharma Ltd
Sillajen Biotherapeutics
Solvotrin Therapeutics Ltd
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
SuviCa Inc
Symphogen A/S
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Company Ltd
Tara Immuno-Oncology Therapeutics LLC
Targovax ASA
Tarveda Therapeutics Inc
Theravectys SA
Tiltan Pharma Ltd
Tocagen Inc
TRACON Pharmaceuticals Inc
Transgene SA
TyrNovo Ltd
United BioPharma Inc
Vaccinex Inc
VasGene Therapeutics Inc
Vaximm AG
Verastem Inc
Vertex Pharmaceuticals Inc
Viralytics Ltd
Wilex AG
WntResearch AB
XBiotech Inc
XuanZhu Pharma Co Ltd
Zymeworks Inc
'
Table of Contents
Table of Contents 2
Introduction 12
Colorectal Cancer Overview 13
Therapeutics Development 14
Colorectal Cancer - Therapeutics under Development by Companies 16
Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 36
Colorectal Cancer - Pipeline Products Glance 38
Colorectal Cancer - Products under Development by Companies 42
Colorectal Cancer - Products under Investigation by Universities/Institutes 71
Colorectal Cancer - Companies Involved in Therapeutics Development 74
Colorectal Cancer - Therapeutics Assessment 312
Drug Profiles 359
Colorectal Cancer - Dormant Projects 1545
Colorectal Cancer - Discontinued Products 1576
Colorectal Cancer - Product Development Milestones 1584
Appendix 1593
List of Tables
Number of Products under Development for Colorectal Cancer, H2 2016 65
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2016 66
Number of Products under Development by Companies, H2 2016 68
Number of Products under Development by Companies, H2 2016 (Contd..1) 69
Number of Products under Development by Companies, H2 2016 (Contd..2) 70
Number of Products under Development by Companies, H2 2016 (Contd..3) 71
Number of Products under Development by Companies, H2 2016 (Contd..4) 72
Number of Products under Development by Companies, H2 2016 (Contd..5) 73
Number of Products under Development by Companies, H2 2016 (Contd..6) 74
Number of Products under Development by Companies, H2 2016 (Contd..7) 75
Number of Products under Development by Companies, H2 2016 (Contd..8) 76
Number of Products under Development by Companies, H2 2016 (Contd..9) 77
Number of Products under Development by Companies, H2 2016 (Contd..10) 78
Number of Products under Development by Companies, H2 2016 (Contd..11) 79
Number of Products under Development by Companies, H2 2016 (Contd..12) 80
Number of Products under Development by Companies, H2 2016 (Contd..13) 81
Number of Products under Development by Companies, H2 2016 (Contd..14) 82
Number of Products under Development by Companies, H2 2016 (Contd..15) 83
Number of Products under Development by Companies, H2 2016 (Contd..16) 84
Number of Products under Development by Companies, H2 2016 (Contd..17) 85
Number of Products under Development by Companies, H2 2016 (Contd..18) 86
Number of Products under Investigation by Universities/Institutes, H2 2016 87
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 88
Comparative Analysis by Late Stage Development, H2 2016 89
Comparative Analysis by Clinical Stage Development, H2 2016 90
Comparative Analysis by Early Stage Development, H2 2016 91
Comparative Analysis by Unknown Stage Development, H2 2016 92
Products under Development by Companies, H2 2016 93
Products under Development by Companies, H2 2016 (Contd..1) 94
Products under Development by Companies, H2 2016 (Contd..2) 95
Products under Development by Companies, H2 2016 (Contd..3) 96
Products under Development by Companies, H2 2016 (Contd..4) 97
Products under Development by Companies, H2 2016 (Contd..5) 98
Products under Development by Companies, H2 2016 (Contd..6) 99
Products under Development by Companies, H2 2016 (Contd..7) 100
Products under Development by Companies, H2 2016 (Contd..8) 101
Products under Development by Companies, H2 2016 (Contd..9) 102
Products under Development by Companies, H2 2016 (Contd..10) 103
Products under Development by Companies, H2 2016 (Contd..11) 104
Products under Development by Companies, H2 2016 (Contd..12) 105
Products under Development by Companies, H2 2016 (Contd..13) 106
Products under Development by Companies, H2 2016 (Contd..14) 107
Products under Development by Companies, H2 2016 (Contd..15) 108
Products under Development by Companies, H2 2016 (Contd..16) 109
Products under Development by Companies, H2 2016 (Contd..17) 110
Products under Development by Companies, H2 2016 (Contd..18) 111
Products under Development by Companies, H2 2016 (Contd..19) 112
Products under Development by Companies, H2 2016 (Contd..20) 113
Products under Development by Companies, H2 2016 (Contd..21) 114
Products under Development by Companies, H2 2016 (Contd..22) 115
Products under Development by Companies, H2 2016 (Contd..23) 116
Products under Development by Companies, H2 2016 (Contd..24) 117
Products under Development by Companies, H2 2016 (Contd..25) 118
Products under Development by Companies, H2 2016 (Contd..26) 119
Products under Development by Companies, H2 2016 (Contd..27) 120
Products under Development by Companies, H2 2016 (Contd..28) 121
Products under Investigation by Universities/Institutes, H2 2016 122
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 123
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 124
Colorectal Cancer - Pipeline by 2cureX ApS, H2 2016 125
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 126
Colorectal Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016 127
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2016 128
Colorectal Cancer - Pipeline by 4SC AG, H2 2016 129
Colorectal Cancer - Pipeline by AB Science SA, H2 2016 130
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2016 131
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2016 132
Colorectal Cancer - Pipeline by Accelerated Pharma Inc, H2 2016 133
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2016 134
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2016 135
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 136
Colorectal Cancer - Pipeline by Alchemia Ltd, H2 2016 137
Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2016 138
Colorectal Cancer - Pipeline by Amal Therapeutics SA, H2 2016 139
Colorectal Cancer - Pipeline by amcure GmbH, H2 2016 140
Colorectal Cancer - Pipeline by Amgen Inc, H2 2016 141
Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2016 142
Colorectal Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 143
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2016 144
Colorectal Cancer - Pipeline by Aphios Corp, H2 2016 145
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2016 146
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 147
Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 148
Colorectal Cancer - Pipeline by ArQule Inc, H2 2016 149
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2016 150
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2016 151
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 152
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2016 153
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 154
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2016 155
Colorectal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 156
Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 157
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2016 158
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 159
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 160
Colorectal Cancer - Pipeline by Bayer AG, H2 2016 161
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2016 162
Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 163
Colorectal Cancer - Pipeline by Biocon Ltd, H2 2016 164
Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2016 165
Colorectal Cancer - Pipeline by Bionovis SA, H2 2016 166
Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2016 167
Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016 168
Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 169
Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2016 170
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 171
Colorectal Cancer - Pipeline by Burzynski Research Institute Inc, H2 2016 172
Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 173
Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2016 174
Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2016 175
Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 176
Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016 177
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016 178
Colorectal Cancer - Pipeline by Celgene Corp, H2 2016 179
Colorectal Cancer - Pipeline by Cellceutix Corp, H2 2016 180
Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 181
Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 182
Colorectal Cancer - Pipeline by Celltrion Inc, H2 2016 183
Colorectal Cancer - Pipeline by Celyad SA, H2 2016 184
Colorectal Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 185
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 186
Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2016 187
Colorectal Cancer - Pipeline by Cipla Ltd, H2 2016 188
Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2016 189
Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2016 190
Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2016 191
Colorectal Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 192
Colorectal Cancer - Pipeline by Compugen Ltd, H2 2016 193
Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 194
Colorectal Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 195
Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 196
Colorectal Cancer - Pipeline by CrystalGenomics Inc, H2 2016 197
Colorectal Cancer - Pipeline by Cytune Pharma SAS, H2 2016 198
Colorectal Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 199
Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H2 2016 200
Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 201
Colorectal Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 202
Colorectal Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 203
Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 204
Colorectal Cancer - Pipeline by EirGenix Inc, H2 2016 205
Colorectal Cancer - Pipeline by Eisai Co Ltd, H2 2016 206
Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2016 207
Colorectal Cancer - Pipeline by Endor Nanotechnologies SL, H2 2016 208
Colorectal Cancer - Pipeline by enGene Inc, H2 2016 209
Colorectal Cancer - Pipeline by EnGeneIC Ltd, H2 2016 210
Colorectal Cancer - Pipeline by Ensol Biosciences Inc, H2 2016 211
Colorectal Cancer - Pipeline by EntreChem SL, H2 2016 212
Colorectal Cancer - Pipeline by Enzo Biochem Inc, H2 2016 213
Colorectal Cancer - Pipeline by Etubics Corp, H2 2016 214
Colorectal Cancer - Pipeline by Exelixis Inc, H2 2016 215
Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 216
Colorectal Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016 217
Colorectal Cancer - Pipeline by Formosa Laboratories Inc, H2 2016 218
Colorectal Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 220
Colorectal Cancer - Pipeline by Genentech Inc, H2 2016 221
Colorectal Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 222
Colorectal Cancer - Pipeline by Genoscience Pharma, H2 2016 223
Colorectal Cancer - Pipeline by Genzyme Corp, H2 2016 224
Colorectal Cancer - Pipeline by Gilead Sciences Inc, H2 2016 225
Colorectal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 226
Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2016 227
Colorectal Cancer - Pipeline by Golden Biotechnology Corp, H2 2016 228
Colorectal Cancer - Pipeline by Green Cross Corp, H2 2016 229
Colorectal Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 230
Colorectal Cancer - Pipeline by Handok Inc, H2 2016 231
Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 232
Colorectal Cancer - Pipeline by Heat Biologics Inc, H2 2016 233
Colorectal Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016 234
Colorectal Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 235
Colorectal Cancer - Pipeline by iDD biotech SAS, H2 2016 236
Colorectal Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 237
Colorectal Cancer - Pipeline by Ignyta Inc, H2 2016 238
Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd, H2 2016 239
Colorectal Cancer - Pipeline by ImmuneXcite Inc, H2 2016 240
Colorectal Cancer - Pipeline by Immunomedics Inc, H2 2016 241
Colorectal Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016 242
Colorectal Cancer - Pipeline by Incanthera Ltd, H2 2016 243
Colorectal Cancer - Pipeline by Incyte Corp, H2 2016 244
Colorectal Cancer - Pipeline by Innovent Biologics Inc, H2 2016 245
Colorectal Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 246
Colorectal Cancer - Pipeline by Interprotein Corp, H2 2016 247
Colorectal Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 248
Colorectal Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 249
Colorectal Cancer - Pipeline by IPD Therapeutics BV, H2 2016 250
Colorectal Cancer - Pipeline by Isofol Medical AB, H2 2016 251
Colorectal Cancer - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 252
Colorectal Cancer - Pipeline by JHL Biotech Inc, H2 2016 253
Colorectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 254
Colorectal Cancer - Pipeline by Johnson & Johnson, H2 2016 255
Colorectal Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 256
Colorectal Cancer - Pipeline by Kancera AB, H2 2016 257
Colorectal Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 258
Colorectal Cancer - Pipeline by Kura Oncology Inc, H2 2016 259
Colorectal Cancer - Pipeline by Laboratorio ELEA SACIF y A, H2 2016 260
Colorectal Cancer - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016 261
Colorectal Cancer - Pipeline by Lion Biotechnologies Inc, H2 2016 262
Colorectal Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H2 2016 263
Colorectal Cancer - Pipeline by Loxo Oncology, Inc., H2 2016 264
Colorectal Cancer - Pipeline by Mabion SA, H2 2016 265
Colorectal Cancer - Pipeline by Mabtech Ltd, H2 2016 266
Colorectal Cancer - Pipeline by mAbxience SA, H2 2016 267
Colorectal Cancer - Pipeline by MacroGenics Inc, H2 2016 268
Colorectal Cancer - Pipeline by Marina Biotech Inc, H2 2016 269
Colorectal Cancer - Pipeline by MediaPharma srl, H2 2016 270
Colorectal Cancer - Pipeline by MedImmune LLC, H2 2016 271
Colorectal Cancer - Pipeline by Medinet Co Ltd, H2 2016 272
Colorectal Cancer - Pipeline by Merck & Co Inc, H2 2016 273
Colorectal Cancer - Pipeline by Merck KGaA, H2 2016 274
Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 275
Colorectal Cancer - Pipeline by Merus NV, H2 2016 276
Colorectal Cancer - Pipeline by Microlin Bio, Inc., H2 2016 277
Colorectal Cancer - Pipeline by MolMed SpA, H2 2016 278
Colorectal Cancer - Pipeline by Mologen AG, H2 2016 279
Colorectal Cancer - Pipeline by Morphotek Inc, H2 2016 280
Colorectal Cancer - Pipeline by Multimmune GmbH, H2 2016 281
Colorectal Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 282
Colorectal Cancer - Pipeline by Natco Pharma Ltd, H2 2016 283
Colorectal Cancer - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016 284
Colorectal Cancer - Pipeline by Nektar Therapeutics, H2 2016 285
Colorectal Cancer - Pipeline by Neovacs SA, H2 2016 286
Colorectal Cancer - Pipeline by Nerviano Medical Sciences Srl, H2 2016 287
Colorectal Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 288
Colorectal Cancer - Pipeline by NormOxys Inc, H2 2016 289
Colorectal Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 290
Colorectal Cancer - Pipeline by Novartis AG, H2 2016 291
Colorectal Cancer - Pipeline by Novogen Ltd, H2 2016 292
Colorectal Cancer - Pipeline by Noxxon Pharma AG, H2 2016 293
Colorectal Cancer - Pipeline by NuCana BioMed Ltd, H2 2016 294
Colorectal Cancer - Pipeline by OBI Pharma Inc, H2 2016 295
Colorectal Cancer - Pipeline by Oncobiologics Inc, H2 2016 296
Colorectal Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 297
Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 298
Colorectal Cancer - Pipeline by Onconova Therapeutics Inc, H2 2016 299
Colorectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 300
List of Figures
Number of Products under Development for Colorectal Cancer, H2 2016 65
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2016 66
Number of Products under Development by Companies, H2 2016 67
Number of Products under Investigation by Universities/Institutes, H2 2016 87
Comparative Analysis by Late Stage Development, H2 2016 89
Comparative Analysis by Clinical Stage Development, H2 2016 90
Comparative Analysis by Early Stage Products, H2 2016 91
Assessment by Monotherapy Products, H2 2016 363
Assessment by Combination Products, H2 2016 364
Number of Products by Top 10 Targets, H2 2016 365
Number of Products by Stage and Top 10 Targets, H2 2016 365
Number of Products by Top 10 Mechanism of Actions, H2 2016 385
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 385
Number of Products by Top 10 Routes of Administration, H2 2016 406
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 406
Number of Products by Top 10 Molecule Types, H2 2016 408
Number of Products by Stage and Top 10 Molecule Types, H2 2016 408
